Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer (MBC) Patients: a Randomized Phase II Study - ERICA Trial

NCT05833919 is registered in ClinicalTrials.gov with Consorzio Oncotech as lead sponsor.

NCT NCT05833919
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05833919 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer (MBC) Patients: a Randomized Phase II Study - ERICA Trial
Lead sponsor
Consorzio Oncotech
Phase
Phase 2
Overall status
Unknown status
Start date
July 30, 2018
Completion date
July 31, 2023
Enrollment
122 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer